| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -4,837,738 |
| Issuance of common stock for services | 726,248 |
| Amortization of prepaid stock based expenses | 3,024,605 |
| Foreign currency transaction loss (gain) | -34,699 |
| Depreciation expense | 125 |
| Amortization of debt discounts | 150,902 |
| Amortization of right-of-use assets | 3,577 |
| Change in fair value of derivative liabilities | -19,706 |
| Loss (gain) on extinguishment of debt, net | 195,861 |
| Non-cash interest expense | 4,906 |
| Accretion of put premium | -37,450 |
| Gst receivable | 3,043 |
| Prepaid expenses | 362,329 |
| Other current assets | 7,438 |
| Accounts payable | -186,804 |
| Employee benefit liability | 13,982 |
| Accrued expenses and other payables | -361,479 |
| Accrued interest | -3,298 |
| Operating lease liability | 2,723 |
| Net cash used in operating activities | -1,939,067 |
| Purchase of equipment | 2,491 |
| Net cash used in investing activities | -2,491 |
| Proceeds from convertible promissory notes, net of original issue discounts and issue costs | 100,000 |
| Repayment of convertible notes | 203,350 |
| Repayment of notes | 671,777 |
| Repayment of loans payable - related party | 150,808 |
| Proceeds from the sale of common stock, net of offering costs | 3,314,458 |
| Proceeds from note payable | 75,000 |
| Proceeds from loans payable - related parties | 78,249 |
| Deferred offering costs | 15,000 |
| Net cash provided by financing activities | 2,526,772 |
| Effect of exchange rate changes on cash | 5,435 |
| Net increase (decrease) in cash | 590,649 |
| Cash and cash equivalents at beginning of period | 12,088 |
| Cash and cash equivalents at end of period | 602,737 |
Propanc Biopharma, Inc. (PPCB)
Propanc Biopharma, Inc. (PPCB)